| Literature DB >> 27121473 |
Wesley J Woollard1, Venu Pullabhatla2, Anna Lorenc2, Varsha M Patel1, Rosie M Butler1, Anthony Bayega1, Nelema Begum1, Farrah Bakr1, Kiran Dedhia1, Joshua Fisher1, Silvia Aguilar-Duran1, Charlotte Flanagan1, Aria A Ghasemi1, Ricarda M Hoffmann1, Nubia Castillo-Mosquera1, Elisabeth A Nuttall1, Arisa Paul1, Ceri A Roberts1, Emmanouil G Solomonidis1, Rebecca Tarrant1, Antoinette Yoxall1, Carl Z Beyers1, Silvia Ferreira1, Isabella Tosi1, Michael A Simpson3, Emanuele de Rinaldis2, Tracey J Mitchell1, Sean J Whittaker1.
Abstract
Sézary syndrome (SS) is a leukemic variant of cutaneous T-cell lymphoma (CTCL) and represents an ideal model for study of T-cell transformation. We describe whole-exome and single-nucleotide polymorphism array-based copy number analyses of CD4(+) tumor cells from untreated patients at diagnosis and targeted resequencing of 101 SS cases. A total of 824 somatic nonsynonymous gene variants were identified including indels, stop-gain/loss, splice variants, and recurrent gene variants indicative of considerable molecular heterogeneity. Driver genes identified using MutSigCV include POT1, which has not been previously reported in CTCL; and TP53 and DNMT3A, which were also identified consistent with previous reports. Mutations in PLCG1 were detected in 11% of tumors including novel variants not previously described in SS. This study is also the first to show BRCA2 defects in a significant proportion (14%) of SS tumors. Aberrations in PRKCQ were found to occur in 20% of tumors highlighting selection for activation of T-cell receptor/NF-κB signaling. A complex but consistent pattern of copy number variants (CNVs) was detected and many CNVs involved genes identified as putative drivers. Frequent defects involving the POT1 and ATM genes responsible for telomere maintenance were detected and may contribute to genomic instability in SS. Genomic aberrations identified were enriched for genes implicated in cell survival and fate, specifically PDGFR, ERK, JAK STAT, MAPK, and TCR/NF-κB signaling; epigenetic regulation (DNMT3A, ASLX3, TET1-3); and homologous recombination (RAD51C, BRCA2, POLD1). This study now provides the basis for a detailed functional analysis of malignant transformation of mature T cells and improved patient stratification and treatment.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27121473 DOI: 10.1182/blood-2016-02-699843
Source DB: PubMed Journal: Blood ISSN: 0006-4971 Impact factor: 22.113